Gleevec in Relapsed/Refractory T Cell Non-Hodgkin's Lymphoma
Status:
Completed
Trial end date:
2013-10-01
Target enrollment:
Participant gender:
Summary
The purpose of this research study is to evaluate the overall response rate to imatinib
mesylate in participants with relapsed or refractory T cell non-Hodgkin's lymphoma. This drug
has been used in chronic myeloid leukemia and information from those other research studies
suggests that it may help to treat T cell non-Hodgkin's lymphoma.